NCT05628636View on ClinicalTrials.gov

AC-OLE-01-VA Tolerability Study in Healthy Participants Under Different Dosing Conditions

PHASE1CompletedINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

November 14, 2022

Primary Completion Date

December 22, 2022

Study Completion Date

April 3, 2023

Conditions

Alzheimer Disease

Interventions

DRUG

AC-OLE-01-VA

formulation of tricaprilin

Trial Locations (1)

4006

RDC Clinical, Newstead

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Cerecin

INDUSTRY

NCT05628636 - AC-OLE-01-VA Tolerability Study in Healthy Participants Under Different Dosing Conditions | Biotech Hunter | Biotech Hunter